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Summary 
Diabetic patients have 2-4 fold increased risk of cardiovascular disease events, and 
have about 60 % increased risk of early mortality. Endothelial cells are sensitive for a 
hyperglycaemic environment. Excess glucose entering the hexosamine pathway is 
thought to elevate O-linked glycosylation (O-GlcNAcylation) of various 
nucleocytoplasmic proteins leading to endothelial dysfunction, insulin resistance, 
diabetes and diabetic complications.  
Numerous transcription factors are regulated by O-GlcNAcylation. Glucose was 
recently reported to function as a direct agonist of the transcription factor liver X 
receptor (LXR). However, direct binding of the hydrophilic glucose molecule to the 
hydrophobic pocket in LXR suggests that glucose may rather act via downstream 
glucose signalling pathways. Preliminary data in our group indicates that LXRβ is 
target for O-GlcNAcylation in response to glucose in human THP-1 macrophages and 
HepG2 cells. O-GlcNAcylation prediction search (1) reveal several potential LXR O-
GlcNAc sites.  
The expression of the Id (inhibitors of DNA binding and differentiation) transcription 
repressors are increased in atherosclerosis and inflammation. D-glucose is shown to 
regulate Id1 protein expression in some cell types and previous work in our group 
have shown that Id2 is up-regulated by hyperglycaemia via the hexosamine signalling 
pathway and is a target for O-GlcNAcylation in J774.2 murine macrophages. The 
effects of D-glucose and O-GlcNAcylation of LXR and Id proteins in human 
endothelial cells have not previously been studied.  
The aims of this master thesis were to study the effects of D-glucose and the O-
GlcNAcase inhibitor NAG-thiazoline on overall protein O-GlcNAcylation level in 
HUVEC. Specific aims were to study whether LXR and Id are targets for O-GlcNAc 
modification and whether Id protein levels are regulated by hyperglycaemia. All 
experiments were performed in human umbilical vein endothelial cells (HUVEC). 
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Endothelial cells from human umbilical cords were isolated and cultured in vitro. The 
cells were incubated with D-glucose (1, 2.5, 5 or 25 mM) or NAG-thiazoline (10, 20 
or 40 µM) for different times and whole cell lysates or nuclear extracts were 
prepared. N- and O-GlcNAcylated proteins were precipitated using succinylated 
wheat germ agglutinin (sWGA). Id or LXRβ proteins were immunoprecipitated by 
their respective antibodies. Finally, samples were separated by SDS-PAGE and total 
O-GlcNAcylated protein level, Id1, Id2, Id3, LXRα/β and LXRβ protein expression 
were determined by western blotting.  
We revealed that NAG-thiazoline is 10 times more potent than PUGNAc, and 10 µM 
is enough to induce overall protein O-GlcNAcylation levels in HUVEC. Furthermore, 
our data indicates that Id1 is a target for O-GlcNAcylation, and Id1 protein 
expression is in contrast to Id3 not up-regulated by D-glucose and NAG-thiazoline. 
LXRβ is a promising target for O-GlcNAcylation. However, further experiments are 
needed in order to make firm conclusions.  
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1. Introduction 
The cells use energy continuously, but the body experiences alternate food supply 
and fasting. The brain, red blood cells and renal medulla require glucose as their 
energy source and need a stable supply of glucose for normal function (2;3). The 
blood glucose is stabilized close to 5 mM determined mainly by the ratio between 
insulin and the counteracting hormones glucagon, cortisol, epinephrine and growth 
hormone (3).  
Glucose absorbed from meals is the main stimulus for insulin secretion. Insulin is an 
anabolic hormone produced by the pancreatic β-cells. Insulin stimulates uptake of 
glucose into adipose tissue and muscle, favours the synthesis of glycogen (in liver 
and muscle), triacylglycerols (in adipose tissue and liver) and proteins (in most 
tissues) (3). Insulin also interacts with receptors in hypothalamus repressing anabolic 
signals while simultaneously activating catabolic signals (4).  
Hyperglycaemia is first manifested as an elevation of postprandial blood glucose 
caused by insulin resistance in target tissues, leading to reduced glucose uptake in 
muscle, adipose tissue and liver and increased glucose production by the liver and 
kidney. Insulin resistance in adipocytes leads to increased level of free fatty acids in 
the circulation, and increased transport of free fatty acids into muscle, liver and β-
cells further impairs insulin secretion and insulin action (5;6). Insulin resistance in 
hypothalamus causes hyperphagia and weight gain (4) thus establishing a vicious 
circle. 
Insulin resistance generally leads to compensatory insulin production leading to 
hyperinsulinemia (7). When the pancreas is unable to produce enough insulin to meet 
the increased need, the blood glucose will rise (8) and eventually diabetes develops. 
Hyperglycaemia is a characteristic feature of diabetes mellitus, and the current 
diagnostic criteria for diabetes mellitus as stated by WHO are fasting plasma glucose 
≥ 7.0 mM or ≥ 11.1 mM in venous plasma two hours after ingestion of 75 gram 
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glucose (9). The group diagnosed by these criteria has a significantly increased risk 
of micro- and macrovascular complications and premature mortality (10). 
The consumption of refined sugars has increased considerable during the last decades 
(11). In general, refined sugars (sucrose, fructose, glucose, starch hydrolysates, i.e. 
glucose syrup, high-fructose syrup etc.), are absorbed more rapidly than 
carbohydrates from starch or fibre containing foods, resulting in a rapid increase in 
the blood glucose (12;13). The postprandial glucose concentration in healthy 
individuals may reach 7-8 mM (14-16). Even healthy people experiencing repeated 
postprandial hyperglycaemic peaks have increased risk of cardiovascular diseases 
(15;17;18). 
1.1 Endothelial cells and hyperglycaemia  
Most cell types are able to reduce their uptake of glucose during periods of 
hyperglycaemia, and their intracellular glucose concentrations remains nearly 
constant. Endothelial cells are however, not able to control their uptake of glucose, 
and thus extracellular hyperglycaemia leads to intracellular hyperglycaemia (19;20). 
Endothelial cells form a barrier (the endothelium) between the vascular smooth 
muscle cells (VSMC) and the blood constituents. Endothelial cells synthesis various 
paracrine acting substances that influence vascular tone and permeability, coagulation 
and fibrinolysis, the composition of the subendothelial matrix, the adhesion and 
transmigration of leukocytes, and inflammatory activity in the vessel wall (10;21;22). 
Endothelial cells also interact with other cell types such as VSMC, platelets, and 
leukocytes (10). 
Both insulin resistance and hyperglycaemia affect the development of endothelial 
dysfunction (23). Dysfunction of the endothelium is regarded as an important initial 
factor in the pathogenesis of atherosclerosis (10;22). Atherosclerosis is a progressive 
disease of large and medium-sized arteries, characterized by adherence of monocytes 
to the endothelium and diapedese and differentiation of monocytes to macrophages in 
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the tunica intima, uptake of oxidized low density lipoproteins (oxLDL) via scavenger 
receptors and transformation of macrophages to lipid rich foam cells that secrete 
proinflammatory cytokines and finally disrupts and thus contribute to lipid depositing 
and plaque formation (24;25).  
1.2 Macromolecules function as signal molecules 
The prevalence of people diagnosed with diabetes is estimated to rise considerably 
and is expected to include at least 366 million people in 2030 (26). 
Type 2 diabetes accounts for around 90 % of all diabetes worldwide (27), and is a 
multifactorial disease with an environmental and genetic component. Excess nutrient 
intake plays a major role in the pathogenesis of the disease. Macromolecules like 
glucose, amino acids and fatty acids, function as signal molecules in nutrient sensing 
pathways. The hexosamine signalling pathway (HSP) is a nutrient signalling pathway 
activated by increased glucose flux (28), but is also sensitive to fluctuations in the 
concentration of free fatty acids, amino acids and the synthesis of nucleotides (29). 
Increased flux through the HSP is linked to insulin resistance. (30). 
1.3 Hyperglycaemia increases metabolism through four 
metabolic pathways  
The molecular mechanisms by which hyperglycaemia causes diabetic complications 
is not clear. In a cell susceptible for a hyperglycaemic environment, the intracellular 
glucose concentration is high and more glucose is metabolised via glycolysis and the 
tricarboxylic acid cycle (TCA), generating more electrons into the electron transport 
chain by NADH and FADH. The flux through the electron transport chain increases 
until a critical threshold occurs where the electron transfer inside the complex III is 
blocked. The surplus electrons are delivered to molecular oxygen, thereby generating 
superoxide (20). Superoxide inhibits the glycolytic enzyme glyceraldehyde-3 
phosphate dehydrogenase (GAPDH) directing the glycolytic intermediates to four 
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different pathways; the polyol pathway, formation of advanced glycation end-product 
(AGE), activation of protein kinase C (PKC) and increased flux through the 
hexosamine pathway (Figure 1.1).      
 
 
 
Figure 1.1. Hyperglycaemia activates four metabolic pathways, leading to 
cellular damage. 
Hyperglycaemia induces overproduction of superoxide by the mitochondria. 
Superoxide inhibits the enzyme GAPDH, thereby generating more substrate for 
four different pathways; increased flux through the polyol pathway, increased 
formation of advanced glycation end‐product (AGE), activation of protein kinase C 
(PKC) and increased flux through the hexosamine pathway. The figure is adapted 
from Brownlee. M. (19;20). 
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1.4 The hexosamine pathway 
Glucose enters the cells via glucose transporters (GLUTs) and is subsequently 
phosphorylated to Glucose-6-phosphate by hexokinase (glucokinase in the liver). 
About 99 % of the intracellular glucose enters the glycolytic pathway or is converted 
to glycogen. 2-5 % of the glucose entering the cell is diverted into the hexosamine 
pathway (Figure 1.2) (31).  
 
 
Figure 1.2. The hexosamine signalling pathway. 
Fructose‐6‐phosphate is converted to glucosamine‐6‐phosphate by the rate 
limiting enzyme GFAT (L‐glutamine:D‐fructose‐6‐phosphate amidotransferase). 
UDP‐GlcNAc is a building block for the formation of complex proteoglycans and 
glycoproteins in the secretory pathway and for O‐GlcNAc modification of 
nucleocytoplasmic proteins (30;32). Figure from (33).  
 
The rate limiting enzyme glutamine:fructose-6-phosphate amidotransferase (GFAT) 
catalyzes the formation of glucosamine-6-phosphate from fructose-6-phosphate and 
the aminodonor glutamine. GFAT is the rate limiting enzyme in the synthesis of 
glucosamine and is tightly regulated allosterically by UDP-GlcNAc and by PKA 
dependent phosphorylation (34;35). GFAT activity is found in almost every tissue 
examined (36), but the two gene products GFAT1 and GFAT2 have different tissue 
distribution patterns; GFAT1 is widely expressed, whereas GFAT2 is mainly 
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expressed in the central nervous system (36;37). GFAT1 activity is in contrast to 
GFAT2 activity increased by cAMP (PKA), indicating that different tissues 
metabolize glucose differently (36). 
GFAT activity in adipocytes is down-regulated by insulin, glucose and glutamine 
(38). In myotubes, GFAT expression is increased by saturated fatty acids (39). GFAT 
is inhibited by the glutamine antagonists azaserine and 6-diazo-5 oxo-norleucine 
(DON) (40). 
Glucosamine 6-phosphate is finally converted to UDP-GlcNAc. UDP-GlcNAc serves 
as a building block for the synthesis of proteoglycans and glycoproteins in the 
secretory pathway, and is also substrate for O-linked glycosylation (O-
GlcNAcylation) of nucleocytoplasmic proteins (30).   
1.5 O-GlcNAcylation and O-phosphorylation 
O-GlcNAcylation is a dynamic posttranslational modification on intracellular 
proteins. O-GlcNAc consists of an O-linked attachment of a single N-
acetylglucosamine on serine and threonine residues of nuclear and cytoplasmic 
proteins (Figure 1.3) (32;41). The conserved enzyme O-GlcNAc transferase (OGT) 
catalyzes the addition and O-GlcNAcase the removal of the O-GlcNAc (Figure 1.3). 
The modification is crucial for life and involved in signal transduction, translation, 
transcription and protein degradation (42). 
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Figure 1.3. Dynamic interplay between O-GlcNAcylation and O-
phosphorylation. 
O‐GlcNAc and O‐phosphate share many common traits. Both O‐GlcNAc and O‐
phosphate occurs on serine and threonine residues. The modifications can be 
found alone, they may compete for the same site, or several modifications can be 
found on the same protein. On some proteins O‐GlcNAcylation and 
phosphorylation modify each other in a reciprocal manner. Figure from (43). 
 
O-GlcNAcylation/de-O-GlcNAcylation is comparable with phosphorylation/de-
phosphorylation (Figure 1.3). Like phosphorylation, O-GlcNAcylation is a dynamic 
posttranslational modification on intracellular proteins. Both modifications are found 
on serine or threonine in response to cellular signals, and the modified protein may 
have altered function. On some proteins, O-GlcNAc and O-phosphate compete for 
the same serine or threonine. The modifications may also be found on adjacent 
residues and may influence the other modification in a reciprocal manner. Several 
known phosphorylation sites are known O-GlcNAcylation sites, and multiple O-
GlcNAcylation- and phosphorylation sites can be found on the same protein (31;43). 
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1.6 O-GlcNAc transferase (OGT)  
O-GlcNAc transferase (OGT) is expressed in all tissues studied and OGT activity is 
essential for life (44). OGT is encoded by one gene, but alternative splicing generates 
three isoforms. The isoforms have different localization; ncOGT 
(nuclear/cytoplasmic), mOGT (mitochondrial), and sOGT (short OGT localized 
throughout the cell) (29). 
The amount of O-GlcNAc modified proteins differ between subcellular 
compartments (31). Most O-GlcNAcylated proteins are found in the nuclear 
membrane, and listed in decreasing order: nuclei, rough microsomes, golgi, cytosol 
and mitochondria (29). 
OGT is regulated by auto O-GlcNAcylation and tyrosine phosphorylation (Whelan, 
2003, 1047) (29;31).  
The OGT molecule consists of an N-terminal tetratricopeptide repeat (TPR) domain 
containing varying (1 - 16) number of TPR (34 amino acids repeats facilitating 
protein-protein interactions), and a C-terminal catalytic domain containing two 
conserved regions (CDI and CDII) (Figure 1.4) (45;46). Recently it was revealed that 
OGT interacts with a variety of phosphoinositides (PIPs) and it was discovered a PPO 
(PIP-binding activity of OGT) domain in the C-terminal (46). 
 
 
Figure 1.4. OGT primary structure.  
The N‐terminal domain contains varying number of TPRs. The C‐terminal domain 
contains two conserved regions (CDI and CDII) (45). PPO is the recent identified 
PIP‐binding domain (46).  
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In contrast to more than 500 kinases regulating phosphorylation, there is only one 
gene encoding OGT (41). It is not clear how one OGT molecule specifically can 
recognize a huge number of different target proteins, but it is suggested that the UDP-
GlcNAc concentration, OGT protein-protein interactions, OGT phosphorylation and 
OGT glycosylation play a part (44). 
1.7 O-GlcNAcase  
O-GlcNAcase removes the O-GlcNAc from proteins and O-GlcNAcase is found in 
every human tissue examined (47). O-GlcNAcase (protein and activity) is localized 
primarily in the cytosol (90%), and 10 % is found in the nucleus (32). O-GlcNAcase 
is phosphorylated, and it is suggested that it also is regulated by interaction with other 
proteins (42;44). OGT and O-GlcNAcase have been found to sometimes occur in the 
same complex (31). O-GlcNAcase has at least two functional domains, a 
hexosaminidase domain and a histone acetyltransferase (HAT) domain (29). 
Streptozotocin (STZ), PUGNAc (48) and NAG-thiazoline (49) are inhibitors of O-
GlcNAcase. NAG-thiazoline is reported to act more potently than PUGNAc (49), but 
has not previously been used to study O-GlcNAcylation in HUVEC. 
1.8 Functional consequences of O-GlcNAcylation 
O-GlcNAc modifications have been identified on several proteins, including 
transcription factors, RNA polymerase II, kinases, phosphatases, metabolic enzymes, 
proteins in the cytoskeleton, nuclear pore proteins and signalling components 
(31;44;50). Dynamic O-GlcNAcylation is shown to be involved in regulation of 
protein phosphorylation, protein function, protein stability, localization of proteins, 
modulating protein-protein interactions and mediate transcription (44). It is reported 
that acute activation of protein O-GlcNAcylation is a stress response increasing cell 
survival during traumas or injuries (51). Dysregulated O-GlcNAcylation of proteins 
is associated with diseases, such as neurodegenerative diseases and cancer. Sustained 
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increase in O-GlcNAcylation has been associated with the pathogenesis of diabetes 
and diabetic complications (31;32). Increased level of O-GlcNAcylation has also 
been found in atherosclerotic plaque of diabetic patients (52). 
1.9 O-GlcNAcylation in endothelial cells  
Several O-GlcNAcylated proteins in human endotehlial cells are identified, mostly 
proteins in the insulin signalling cascade. Insulin modulates endothelial nitric oxide 
synthase (eNOS) activity and expression through the insulin receptor substrate-1 and-
2 (IRS-1 and IRS2), phosphatidyl inositol 3-kinase (PI3K) and protein kinase B (Akt) 
signalling cascade. NO has vasodilatory effects, protects vessels from injury, 
inflammation and thrombosis, inhibits adherence of leukocytes to the endothelium, 
and reduces platelet aggregability and proliferation of smooth muscle cells (53). It 
has been shown that NO production is inhibited by hyperglycaemia induced O-
GlcNAcylation on IRS1 and -2, p85 and eNOS (32;52), suggesting a role of O-
GlcNAcylation in the pathogenesis of insulin resistance and diabetic complications.  
1.10 Liver X receptor (LXR) 
Liver X receptor (LXR)α and LXRβ constitute the nuclear receptor LXR subfamily. 
LXRβ is ubiquitously expressed, whereas LXRα is expressed mainly in the liver, 
adipose tissue and macrophages (54). LXR target genes have been shown to be 
involved in lipogenesis and cholesterol metabolism, glucose homeostasis, and 
inflammatory responses (54). 
LXR have both favourable and unfavourable effects in diabetes. Favourable effects 
include suppression of proinflammatory cytokines, limitation of effects of 
glucocorticoids, inhibition of gluconeogenesis, lowering glucose levels in serum and 
induction of reverse cholesterol transport. Unfavourable effects include induction of 
fatty acid production and increased triacylglycerols in serum (54). 
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LXR have mostly been studied in liver, adipose tissue and muscle, but the effect of 
LXR in endothelial cells has not been extensively examined. ABCA-1 is an LXR 
target gene involved in reverse cholesterol transport, stimulating cholesterol efflux to 
apolipoproteins. Low density lipoproteins (LDL) is shown to activate LXR and 
induce up-regulation of ABCA-1 expression in endothelial cells (55), whereas 
oxidized low density lipoproteins (oxLDL) inhibits activation of LXR and down-
regulates ABCA-1 expression. OxLDL induced down-regulation of ABCA-1 may 
contribute to endothelial dysfunction and plaque formation (56).  
LXR function as a heterodimer with retinoid X receptor (RXR) (Figure 1.5). The 
LXR-RXR heterodimer is bound to LXR response element (LXRE) in the promoter 
of target genes in complex with corepressors. Upon ligand activation, the heterodimer 
undergoes a conformational change that induces the release of the corepressors and 
recruits coactivators and increase transcription of the LXR target genes. The LXR-
RXR complex acts as a nutrient sensor (57) activated by either LXR ligands, RXR 
ligands or synergistically by ligands of both receptors (57;58). 
 
Figure 1.5. LXR  
Liver X receptors (LXRs) are cholesterol sensing transcription factors. In the 
nucleus, LXR‐retinoid X receptor (RXR) heterodimers are bound to LXR response 
elements (LXREs) in the promoter of target genes with corepressors. Upon ligand 
binding, the corepressors are exchanged for coactivator complexes and 
transcription of target gene is induced. Figure adapted from (59). 
 
Oxygenated derivatives of cholesterol (oxysterols) are natural LXR ligands which 
bind to a hydrophobic pocket in the C terminal domain and activate gene 
transcription of LXR target genes. Recently, it was suggested that glucose binds and 
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regulates LXRα and -β in the liver. Glucose was more potent on LXRβ than LXRα 
(60). However, the hydrophilic nature of the glucose molecule suggests that glucose 
rather acts via downstream glucose signalling pathways, potentially via hexosamine 
signalling pathway and O-GlcNAcylation of LXR. We performed a search for 
potential O-GlcNAcylated sites on LXR using the YinOYang prediction program (1), 
revealing that LXRα (Appendix A) and LXRβ (Appendix A) have several potential 
O-GlcNAcylation sites.  
1.11 Inhibitors of DNA binding and differentiation (Id 
proteins) 
Id (inhibitors of DNA binding and differentiation) family of proteins consists of four 
gene products (Id1-Id4) of similar size (13-20 kDa) (61). Id1 and Id3 have different 
splice variant (62;63). 
The level of Id expression varies among different tissues, and is generally low in un-
proliferating and differentiated cells (64;65). Id1 and Id3 are nearly ubiquitously 
expressed, whereas Id2 is mainly expressed in bone marrow, testis and brain, and Id4 
in testis, brain and kidney (65;66). Id1, Id2 and Id3 are expressed in endothelial cells 
during embryogenesis, however at birth Id genes are down regulated in most mature 
tissues (67). Id3 protein is expressed at low levels in normal vessels, whereas Id2 is 
normally absent from the vessel wall (64). 
The Id family belongs to the helix-loop-helix (HLH) family of transcription factors 
(61;64;68;69). The primary targets for the Id proteins are the basic HLH (bHLH) 
transcription factors (61;64;68;69). Basic HLH transcription factors forms homo- and 
heterodimers that bind DNA sequences termed E-boxes in the promoter region of 
target genes and activate transcription (Figure 1.6). The Id proteins lack the basic 
DNA binding region and form inactive heterodimers with class I of bHLH proteins 
(Figure 1.6).  
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Figure 1.6. The Id proteins act as dominant-negative regulators of transcription.  
Primary targets for Id proteins are the basic helix‐loop‐helix (bHLH) transcription 
factors. The HLH‐region of bHLH mediates dimerization, and the basic region is 
responsible for specifically binding DNA sequences termed E‐boxes (61). Id 
proteins lack the basic region necessary for binding to DNA, and dimers with Id 
proteins are thus unable to activate gene transcription. Figure from (64). 
 
Class II of bHLH proteins are incapable of forming homodimers (with few 
exceptions), and normally form heterodimers with class I proteins. Id proteins thus 
also regulate class II proteins by heterodimerize with class I proteins and prevent 
them from forming heterodimers with class II proteins (61;64;65). Id proteins are also 
shown to dimerize with other bHLH proteins such as SREBP (class III) and proteins 
that do not contain an HLH domain, for example the cell cycle regulator 
retinoblastoma protein (Rb) (64;70).  
The Id proteins regulates several cellular processes, including transcription of cell 
cycle genes, differentiation, haematopoiesis, angiogenesis, neurogenesis, myogenesis, 
and developmental processes (64;67;68). Id expression levels are increased in 
atherosclerosis, inflammation (65) and cancer (69).  
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Dysregulated angiogenesis, the formation of new blood vessels out of pre-existing 
capillaries, is a characteristic of diabetes. Impaired angiogenesis may lead to reduced 
wound healing in peripheral limbs and reduced collateral development of cardiac 
vessels contributing to diabetic ischemia and increased cardiac mortality. However, 
angiogenesis into an atherosclerotic plaque is associated with increased risk of intra 
plaque haemorrhages, plaque rupture and fatal outcome. Diabetic patients have 
increased risk for intra plaque haemorrhage (71). Enhanced angiogenesis have also 
been observed in the retina, contributing to diabetic retinopathy (72).  
Id proteins play a major role in angiogenesis (73). It is shown that overexpression of 
Id can induce angiogenic processes in HUVEC (transmigration, expression of matrix 
metalloproteinases-2 and -9, and tube formation) (74). Id proteins are thought to 
facilitate angiogenesis in tumours (67), and there are similarities between 
angiogenesis in tumours and angiogenesis into plaques (69). 
The effects of hyperglycaemia on angiogenesis are not fully understood. 
Hyperglycaemia is reported to inhibit angiogenic processes in HUVEC (72) and it 
was recently reported that increased level of glucosamine induced O-GlcNAc 
modifications in endothelial cells may contribute to dysregulated angiogenesis (72).  
It is shown that Id1 protein is up-regulated by glucose in pancreatic β-cells (70), and 
previous studies in our group have shown that Id2 is up-regulated by hyperglycaemia 
in murine J774.2 macrophages via the hexosamine signalling pathway (75). 
Preliminary experiments in our laboratory also indicate that Id2 is target for O-
GlcNAcylation (76). It is not known whether Id protein expression in HUVEC is 
regulated by D-glucose, or whether they are targets for O-GlcNAcylation.  
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1.12 Aim of study 
The objective of this study was to identify hyperglycaemia induced O-GlcNAcylated 
proteins in primary human endothelial cells with the aim of elucidate their role in 
endothelial dysfunction with specific focus on the transcription factors Id proteins 
and LXR.  
Specific aims:  
• Test the effect of the O-GlcNAcase inhibitor NAG-thiazoline on protein O-
GlcNAcylation in HUVEC.  
• Study the effect of hyperglycaemia on the total level of O-GlcNAcylated 
proteins in HUVEC  
• Study whether D-glucose regulates Id protein expression and whether they are 
targets of O-GlcNAcylation in HUVEC 
• Study whether LXR is a target of O-GlcNAcylation in HUVEC  
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2. Methods 
Materials 
Amersham Hyperfilm™ ECL  GE Healthcare, UK  
Bűrker Haemacytomer Marlenfield, Germany 
Cell culture plastic plates (6 wells) BD Labware, USA 
Cell scraper Sigma Aldrich, Germany 
Criterion™ gel system Bio-Rad, USA  
Criterion Precast gel (4-20 %), 18 wells Bio-Rad, USA  
Criterion Precast gel (4-20 %), 12 wells Bio-Rad, USA  
Criterion Precast gel (12+ %) Bio-Rad, USA 
Criterion Precast gel (7.5 %) Bio-Rad, USA  
Criterion Precast gel (10 %), 18 wells Bio-Rad, USA  
Criterion Precast gel (10 %), 12 wells Bio-Rad, USA  
ELISA microplate (96 well) Greiner bio-one, Germany 
Eppendorf tubes (1.5 ml) Sarstedt, Germany 
Falcon tubes (5 ml, 15 ml) BD Labware, USA 
Hypercassette™ autoradiography cassettes  Amersham, UK 
Immobilon™ Transfer Membrane (PVDF) Millipore, USA  
Mesoft compresses   Tendra, Sweden 
Metal cannulas Technical Department, UIO 
Omnifix® single use syringes (10 ml, 50 ml) Braun, Germany 
Pipetboy  INTEGRA Biosciences AG, Switzerland 
Single use scalpel Paragon®, UK 
Sterican sterile needle Regent, USA 
Sterile cell culture flasks (25, 75, 150 cm2) BD Labware, USA 
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Sterile filter flasks TPP, Switzerland 
Sterile surgical gloves with biogel coating Regent, USA 
Stripettes (5 ml, 10 ml, 25 ml) BD Labware, Germany 
Whatman® filter paper Schleicher & Schuell  
  
Instruments 
Celloshaker variospeed Vialta, Italy 
Centrifuge Kubota 5930 Kubota, Japan 
Centrifuge 5417 R Eppendorf, Germany 
Dri Block Heater   Total Lab Systems Ltd, New Zealand 
Kodak X-OMAT, 1000 Processor Kodak 
Incubator  Forma  Scientific Incorporation, USA 
Mettler Toledo Model AX105DR Delta Range 
Scale® 
Mettler, Norway 
Microscope Olympus (CKX 415F) Olympus Corp., Japan 
pH-meter: PHM210 MeterLab®, France                                     
Titertek Multiskan PLUS Eflab, Finland 
Rotating device: Ld-76 Labinco B.V. The Netherlands 
 
Chemicals  
4-(2-Aminoethyl) benzenesulfonyl fluoride 
hydrochloride (AEBSF) 
Calbiochem®, USA  
ALLN Calbiochem®, USA 
BC Assay protein quantification kit  Uptima Interchim, France  
β-mercaptoethanol (C2H6OS) Sigma-Aldrich, Norway 
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Bovine serum albumin (BSA) Sigma Aldrich, Germany 
Bromphenol blue Bio-Rad, USA  
Collagenase (0.2 %) Sigma Aldrich, Germany  
Coomassie Brilliant Blue (G) Sigma Aldrich, Germany  
Complete Mini EDTA-free Protease inhibitor 
cocktail tablets 
Roche, Germany  
D(+)-Glucose Sigma Aldrich, Germany 
Dithiothreitol (DTT) Fermentas, Sweden  
ECL™ Western blotting detection reagent  Amersham, UK  
ECL™ Plus Western blotting detection reagent Amersham, UK  
Ethylenediaminetetraacetic acid (EDTA) Sigma-Aldrich, Germany 
Epidermal growth factor (EGF) R&D systems, UK 
Foetalt bovine serum (FBS) Sigma Aldrich, Germany 
Fibroblast growth factor (FGF) R&D systems, UK 
Fungisone GIBCO Invitrogen, UK 
Glycerol Sigma-Aldrich , Germany  
Glycine Sigma-Aldrich, Germany 
Hydrocortisone  Sigma Aldrich, Germany 
Hydrogen chloride (HCl) Merck, Germany 
Igepal CA-630 (NP-40) Sigma-Aldrich  
Insulin Actrapid® Penfil® Novo Nordisk A/S, Denmark 
KH2PO4  Merck, Germany  
Magnesium chloride (MgCl2) Merck, Germany  
MCDB131 basis powder Sigma Aldrich, USA M8537-1L 
Methanol Merck, Germany 
N-acetylglucosamine (Chitin hydrolysates)  Vector Laboratories, UK 
NAG-thiazoline Gift from Dr. Spencer Knapp (49) 
NaH2PO4 x 2H2O   Merck, Germany 
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Precision Plus Protein Standards (All blue) Bio-Rad, USA  
Precision Plus Protein Standards (Dual color)  Bio-Rad, USA   
RPMI 1640 with L-glutamin, without glucose  Gibco Invitrogen, UK 
Sodium dodecyl sulphate (SDS) Sigma-Aldrich, Norway 
Sodium chloride (NaCl) Merck, Germany 
Sodium fluoride (NaF) Sigma Aldrich, Norway 
Sodium hydrogen carbonates (NaHCO3) Merck, Germany 
Sodium Hydroxide (NaOH) Merck, Germany 
Sodium orthovanadate (N3VO4) Sigma-Aldrich, Germany 
Sodium pyrophosphate (NaPPi) Sigma Aldrich, Germany 
Tris Base   Calbiochem, USA  
Trypan blue solution  Sigma-Aldrich, UK 
Trypsin-EDTA Solution (1x) Sigma-Aldrich, Norway 
Tween® 20 Sigma Aldrich, Germany 
          
Tissues 
Human umbilical cords Rikshospitalet, Oslo 
 
Antibodies 
Id1 (C-20) Rabbit polyclonal IgG antibody  Santa Cruz Biotechnology, Santa Cruz,   
Sc-488 
Id2 (C-20) rabbit polyclonal IgG antibody Santa Cruz Biotechnology, Santa Cruz,     
Sc-489 
Id3 (C-20) rabbit polyclonal IgG antibody Santa Cruz Biotechnology, Santa Cruz,      
Sc-490 
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CTD 110. 6 monoclonal antibody Covance, UK, MMS-248R 
RL-2 mouse monoclonal antibody ABR Affinity BioReagentsTM, USA, 
Cat.No: MA1-072 
LXR α/β (R20) goat polyclonal IgG antibody Santa Cruz Biotechnology, Santa Cruz,     
SC-1206 
Mouse Anti-Human LXR beta / NR1H2 IgG2a, 
Monoclonal Antibody 
R&D, Cat. No:  PP-K8917-10 
β-Actin (C4) mouse monoclonal antibody Santa Cruz Biotechnology, Santa Cruz,      
SC-47778 
Goat Anti-Rabbit IgG secondary antibody Jackson immuno Research, USA,               
Cat. No: 111-035-144 
Goat Anti-Mouse IgG secondary antibody Jackson immuno Research, USA,               
Cat. No: 115-035-146 
Goat Anti-Mouse IgG secondary antibody, light 
chain 
Jackson immuno Research, USA,               
Cat. No: 115-035-174 
Mouse Gamma Globulin Jackson Immuno Research, USA,               
Cat. No: 015-000-002 
Rabbit Gamma Globulin Jackson Immuno Research, USA,               
Cat. No: 011-000-002 
Goat Anti-Mouse IgM secondary antibody Sigma-Aldrich Co, USA,                            
Cat. No: A 8786 
Rabbit Anti-Goat IgG secondary antibody Southern Biotech, USA                              
Cat. No: 6160-05  
OGT (AL28) Gift from Dr. Hart (2003) (77) 
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2.1 Complete MCDB-medium 
Procedure 
The MCDB-powder was transferred to a glass vial containing 850 ml MilliQ-H2O 
and stirred until dissolved. While stirring, 1.18 g sodium hydrogen carbonates 
(NaHCO3) was added, and the pH was adjusted to 7.3. The final volume was adjusted 
to 1000 ml by adding MilliQ-H2O. The medium was sterile filtered through a sterile 
filter flask with a 0.22 microns membrane. The medium was made complete by 
adding sterile epidermal growth factor (EGF) (500 µl), 50 µl fibroblast growth factor 
(FGF), 500 µl gentamicin, 50 µl hydrocortisone, 500 µl fungisone and 7% heat 
inactivated foetal bovine serum (FBS) (table 1).  
2.2 Isolation of Human Umbilical Vein Endothelial Cells 
(HUVEC)  
The inside surface of blood vessels are formed by a single layer of endothelial cells. 
Human Umbilical Vein Endothelial Cells (HUVEC) are primary endothelial cells 
isolated from human umbilical cord vein and were first successfully cultured in vitro 
by Jaffe and Nachman in 1973 (78). HUVEC were obtained from the obstetric and 
gynaecology division, Rikshospitalet, Oslo from healthy mothers with normal 
pregnancies. Written consent was obtained from the mothers and ethical approval 
was obtained from the Human Research Ethical Committee (79).  
Procedure 
HUVEC were isolated from human umbilical cord veins by an adaptation of the 
method of Jaffe et al (78). A sterile technique was utilized in all operations of the 
cord. The cord was placed in a container filled with transporting buffer (Table 2) 
immediately after delivery and stored in the fridge (4oC) for maximum 48 hours. The 
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umbilical vein was cannulated with a metal cannula and a 50 ml sterile syringe was 
coupled to the cannula via a 2-3 cm plastic tube. The vein was perfused with 1x PBS 
(Table 3) to wash out the remaining blood. The other end of the vein was cannulated 
and coupled to a 10 ml syringe and 10 ml of 0.2 % collagenase in 1x PBS was 
infused. The cord containing the 0.2 % collagenase was placed in a glass vial filled 
with sterile 1x PBS at 37oC for 10 minutes, allowing the endothelial cells to separate 
from the vein wall followed by centrifugation for 10 minutes 470 x g. The cell pellet 
was resuspended in 5 ml complete MCDB131-medium, and the cells were transferred 
to a 25 cm2 cell culture flask and incubated at 37oC in a humidified 5 % CO2 
atmosphere. The culture medium was changed the next day to remove blood cells. 
2.3 Culturing and splitting of HUVEC 
The HUVEC were cultured in 25 cm2 cell culture flasks (5 ml pr. flask), 75 cm2 cell 
culture flasks (15 ml pr. flask), or 150 cm2 cell culture flasks (25 ml pr. flask). The 
cells were seeded into 6-well plates (2 ml pr. well) during experiments. The cells 
were fed 3 times a week with a complete change of culture medium. At 80 -100 % 
confluence, the cells were split at a 1:3 ratio. Cells from passages 2-4 were used in all 
experiments. Cells from later passages may have changes in phenotype, and it is 
advised to discard cells beyond the 6th passage (80). 
Endothelial cells adhere to the extracellular matrix and neighbouring cells via 
adhesion molecules. There are both calcium dependent and calcium independent 
mechanisms of cell adhesion. Trypsin is a proteolytic enzyme of the serine protease 
family and Ethylenediaminetetraacetic acid (EDTA) is a metal ions chelator which 
removes Ca2+ ions. Trypsin-EDTA can disrupt both cell-cell and cell-matrix 
interactions, and Trypsin-EDTA solution was used to remove adherent cells from the 
culture surface. 
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Procedure 
Old medium was removed by aspiration, and the cells were washed with 2 ml 
Trypsin-EDTA (1x) solution (2 ml to 25 cm2 culture flask). Trypsin-EDTA (3 ml) 
was added, and the culture flask was incubated at 37oC for 5-6 minutes. The detached 
cells were visualized in microscope as round shaped cells. Complete medium (5 ml) 
containing 7 % FBS was added in order to inhibit further tryptic activity which may 
damage the cells. Calcium and proteins in FBS inhibit Trypsin and Trypsin-like 
activities. After centrifugation at 1500 rotations per minute (rpm), the cell pellet was 
resuspended in complete MCDB131- medium, transferred to 25 cm2, 75 cm2 or 150 
cm2 cell culture flasks, and incubated at 37oC, 5 % CO2.  
2.4 Lysis of cells 
RIPA (Radio-Immunoprecipitation Assay) buffer is used for whole cell lysis and is 
useful when studying total protein level. As soon as lysis occurs, proteolysis, 
deglycosylation, phosphorylation/dephosphorylation and denaturation begin. These 
processes can be slowed down if the samples are kept at 4°C and appropriate 
inhibitors are added fresh to the lysis buffer. In order to avoid deglycosylation after 
lysis, we added NAG-thiazoline, an inhibitor of O-GlcNAcase (49).  
Procedure 
The cells were grown in 6 well plates and stimulated at 80-100 % confluence. The 
MCDB131 medium was replaced with RPMI 1640 medium containing 7 % FBS and 
1 mM D-glucose, without supplements over night. The next day, the cells were 
incubated with various concentrations of NAG-thiazoline or D-glucose as specified in 
the figure legends. All further procedures were performed on ice in order to slow 
down proteolysis. After removing the media by aspiration, the cells were washed two 
times with ice-cold 1x PBS, 1 ml per well. 250 µl Ice-cold RIPA-buffer (Table 4) 
were added pr. well, and the cells were scraped with a cell scraper. The extract was 
then transferred to eppendorf tubes, left on ice for 30 minutes and flicked at intervals 
to dissolve material. The extract was centrifuged 14 000 rpm for 10 minutes at 4oC 
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and the supernatant was transferred to clean eppendorf tubes. The protein 
concentration was measured, and the concentration was adjusted to the same protein 
concentration with RIPA-buffer. The lysates were stored at -80oC or mixed with 
loading dye (2x) (Table 5), boiled for 5 minutes and stored at -20oC until SDS-PAGE 
and western blotting. 
2.5 Preparation of nuclear and cytoplasmic extracts  
Proteins that are found predominantly in the nucleus can be enriched in a nuclear 
lysate. A nuclear protein will constitute a larger proportion of the total protein in a 
nuclear lysate than in a whole-cell lysate, making it easier to obtain a signal from a 
weakly expressed protein.  
Procedure  
The cells were grown in 6 well plates and stimulated at 80-100 % confluence. All 
procedures were performed on ice.  
After removing the media by aspiration the cells were washed two times with ice-
cold 1x PBS (0.5 ml per well). Ice-cold lysis buffer (250 μl) (Table 6) were added pr. 
well, and the cells were scraped with a cell scraper. The cells were transferred to a 
glassgrinder and lysed by moving the pestle up and down ten times. After spinning at 
3500 rpm for 10 minutes at 4oC, the supernatant, which now constituted the 
cytoplasmic extract, were transferred to eppendorf tubes. The nuclear pellets were 
resuspended in 1x PBS. To confirm the presence of nuclei, 40 µl of the resuspended 
pellet were removed and mixed with 40 µl trypan blue. Blue, round shaped nuclei 
were visualized with a light microscope. After centrifugation at 3500 rpm for 10 
minutes at 4oC, the nuclear pellets were resuspended in 100 µl ice cold NE2 lysis 
buffer (Table 7) and left on ice for 30 minutes. The tubes were flicked approximately 
every 10th minutes. The nuclear extracts were diluted to 520 µl with lysis buffer (1x 
PBS containing 0.2 % NP-40) and 20 µl was removed for measuring protein 
concentrations.  
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2.6 Measurement of protein concentration  
The BCA Protein Assay was used to determine the protein concentration of the cell 
lysates. In an alkaline environment proteins will reduce Cu2+ to Cu1+. In the BCA 
assay, this property is combined with a colorimetric detection of Cu1+ by 
bicinchoninic acid (BCA). The amount of Cu2+ reduced is proportional to the amount 
of protein present in the solution.  
Procedure 
Different concentrations of BSA (2 mg/ml stock solution) were used to prepare a 
standard curve. MQ-H2O, BSA and lysis buffer were added to a 96-well plate as 
shown in Table 8. Lysis buffer was added to each standard in the same amount as the 
samples in order to correct for possible buffer effects. The standards were made in 
duplicates. 
Each sample was prepared in triplicates by adding 5 µl of the sample and 45 µl MQ-
H2O to the 96-wells plate. Protein assay reagent A and protein assay reagent B were 
mixed 50:1, and 200 µl of the A + B solution was added to each well. The 96-wells 
plate was incubated at 37oC for 30 minutes before the absorbance was measured at 
562 nm. The absorbance of the BSA standards (y-axis) was plotted against the known 
BSA concentrations (x-axis) and the protein concentration of the samples was 
determined.  
2.7 Immunoprecipitation (IP) 
Immunoprecipitation (IP) is a method by which a protein can be isolated from a 
protein lysate using an antibody specific to the protein of interest. The protein bound 
antibody is then pelleted out of solution by centrifugation following incubation with 
protein A/G agarose beads.  
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Procedure 
Nuclear- or whole-cell lysates were prepared as described. The specific antibody was 
added to the cell lysate and left over night at 4oC on a rotating device. A control 
sample was prepared by adding gamma globulin of the same species in the same 
concentration as the antibody and left over night at 4oC on a rotating device. The next 
morning, both the sample and the control sample were incubated with 25 µl Protein 
A/G PLUS-Agarose beads at 4oC for 1 hour on a rotating device followed by 
centrifugation at 2500 rpm for 1 minute at 4oC. Supernatants (post-IP lysates) were 
transferred to clean eppendorf tubes. The pellets were washed 3 times in lysis buffer 
in order to remove unspecific proteins. The pellets were resuspended in 100 µl 2x 
loading dye, 50 µl post-IP lysate was mixed with 50 µl 2x loading dye, and 50 μl pre-
IP lysate (input control) was mixed with 50 µl 2x loading dye. The samples were 
boiled for 5 minutes and 30 µl was further analyzed by SDS-PAGE and western 
blotting.       
2.8 Precipitation of N- and O-GlcNAcylated proteins 
Succinylated wheat germ agglutinin (sWGA) is a lectin that specifically binds 
terminal O- and N-GlcNAc and is used to precipitate O-and N-GlcNAcylated 
proteins.  
Procedure 
In order to remove agarose binding proteins, lysate (500 µl) was incubated with 25 µl 
Protein A/G PLUS-Agarose beads and incubated at 4oC on a rotating device for 45 
minutes - 1 hour. After centrifugation at 2500 rpm for 1 minute at 4oC, the 
supernatant was transferred to clean eppendorf tubes. The sWGA was washed 3 times 
in lysis buffer and lysates were incubated with 40 µl sWGA (1:1 v/v slurry) at 4oC on 
a rotating device over night. The next day, the samples were centrifuged 1 minute at 
2500 rpm, 4oC, and the sWGA pellets washed 3 times in lysis buffer. The post-
sWGA lysate (50 µl) was transferred to clean eppendorf tubes and mixed with 50 µl 
2x loading dye. The sWGA pellets were resuspended in 100 µl 2x loading dye. Pre-
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precipitation lysates (50 µl) were mixed with 50 µl 2x loading buffer. All the samples 
were boiled for 5 minutes in a heating block before SDS-PAGE and western blotting, 
or stored at -20oC. 
2.9 SDS-PAGE (Sodium dodecyl sulphate-Polyacrylamid 
gel electrophoresis) 
Polyacrylamide gel electrophoresis (PAGE) is the migration of proteins through 
pores in a polyacrylamide gel matrix in response to an electrical field.  
Sodium dodecyl sulphate (SDS) is an anionic detergent which denature the proteins 
(i.e. disrupts the secondary, tertiary and quaternary structure of the proteins) together 
with β-mercaptoethanol and heating. The proteins bind about 1.4 g SDS/g protein, 
and SDS will coat the proteins with negative charges in proportion to their length, 
allowing the proteins to migrate towards the anode.  
The polyacrylamide gel is formed from the polymerization of acrylamide monomers 
in the presence of smaller amounts of the crosslinking agent N,N´-methylene-bis-
acrylamide. When the polymer is formed, it turns into a gel with different pore sizes 
according to the concentration of the acrylamide. Gels with high concentration of 
acrylamide will have smaller pore size than gels with low acrylamide concentration. 
The smaller molecules are able to navigate the smaller pore size more easily than the 
larger molecules, and the proteins are thus separated according to size.   
Procedure 
The cell lysates and IPs were prepared and mixed with 2x loading dye as described 
above and boiled for 5 minutes before loading. The electrophoresis apparatus and 
pre-cast gel was assembled according to manufactures instructions (Bio-Rad). 
Running buffer (Table 9) was poured into the container, and equal amounts of protein 
were loaded into each well. Protein standards were loaded to marginal wells on both 
sides. The SDS-PAGE was run at 120-150 V until the bromphenol blue and protein 
standards reached the bottom of the gel.  
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2.10 Western blotting  
In western blotting assays, an antibody is used to identify a specific protein of interest 
or a post-translational modification (i.e. O-linked glycosylation, phosphorylation) of 
an immunoprecipitated protein or proteins in a lysate separated on the gel. First, the 
SDS-PAGE separated proteins must be transferred from the polyacrylamide gel to an 
Immobilon-Polyvinylidene fluoride (PVDF) membrane by an electric currant in order 
to make the proteins accessible to antibody detection. The proteins maintain the same 
relative position they had in the gel. For enhanced chemiluminescence (ECL) 
detection, the primary antibody is incubated with a secondary antibody conjugated to 
the enzyme horseradish peroxidase (HRP). In the presence of hydrogen peroxide, 
HRP converts luminol to dianion, an excited intermediate which emits light 
(luminescence) when it returns to its ground state. The light produced is in proportion 
to the amount of protein. The light can be captured on a sensitive film. The size of the 
protein can be determined relative to a size marker standard and the protein quantity 
can be determined relative to the intensity of other bands.   
Procedure 
For each gel, one PVDF membrane and four filter papers were cut in the same size as 
the gel. The PVDF membrane was soaked in methanol in order to be compatible with 
aqueous systems. The membrane was rinsed in MQ-H2O and equilibrated in transfer 
buffer (Table 10). Two fiber pads and the filter papers were dipped in transfer buffer 
before the assembly of the cassette. The cassette was assembled in following order: 
red side of the cassette, 1 fiber pad, 2 filter papers, PVDF membrane, gel, 2 filter 
papers, and 1 fiber pad. The red side of the cassette was inserted into the red 
side/anode of the blotting apparatus to allow the negatively charged proteins in the 
gel transfer to the membrane. One cooling block and a stirring bar were placed into 
the container and the container was filled with transfer buffer. The blotting apparatus 
was placed on a magnetic stirrer and transfer conducted at 100 V for 60 minutes. The 
cooling block was replaced after 30 minutes in order to avoid over heating.  
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To avoid unspecific binding, the PVDF membrane was blocked in 3 % BSA-TBST 
for 45-60 minutes. The membrane was thereafter transferred to a 50 ml Falcon tube 
and incubated with the primary antibody diluted in 3 % BSA-TBST at 4oC over night 
on a rolling device. The next day, the membrane was washed 3 x 5 minutes in TBST 
to remove unbound antibody before the membrane was incubated with a HRP-
conjugated secondary antibody diluted in 3 % BSA-TBST for 45 minutes on a shaker 
at room temperature. Next, the membrane was washed twice in MQ-H2O and 
incubated with an ECL solution containing the substrates for HRP. The membrane 
was then placed in a Hypercassette™, the light produced was captured on a film and 
the image developed in a film developer machine. Molecular weight markers were 
used to determine the size of the proteins.  
2.11 Stripping the PVDF membrane 
The PVDF membrane can be stripped for both primary and secondary antibodies and 
be reprobed with new antibodies.   
Procedure 
The membrane was incubated at 50oC for 30 minutes in stripping buffer (Table 11) 
while rotating. The membrane was washed 3 x 5 minutes in TBST (Table 12) and 
reblocked in 3% BSA-TBST for 1 hour at room temperature before reprobing with 
primary- and secondary antibodies as described.  
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3. Results 
3.1 Concentration and time dependent effects of NAG-
thiazoline on protein O-GlcNAcylation in HUVEC 
NAG-thiazoline is reported to be a more potent inhibitor of O-GlcNAcase than 
PUGNAc (49), but has not to date been used to study O-GlcNAcylation in HUVEC. 
NAG-thiazoline is not yet commercially available, and was kindly provided by Dr. 
Spencer Knapp (49).  
To test the dose needed for this inhibitor to increase protein O-GlcNAcylation in 
HUVEC, a dose-response experiment with different NAG concentrations were 
performed. 10 µM NAG-thiazoline was sufficient to induce an increase in overall O-
GlcNAcylation in HUVEC as shown in Figure 3.1A. This is 10 times more potent 
than the optimal PUGNAc concentration used to study O-GlcNAcylation (46;81-84).  
Immunoblot intensities of bands of approximately 55 and 60 kDa were strongest in 
cells incubated with 10 µM NAG-thiazoline compared to 0, 20 and 40 µM (Figure 
3.1A). No further effect of NAG-thiazoline on O-GlcNAcylation was observed in 
cells treated with concentrations above 10 µM (Figure 1A).  
The difference in total O-GlcNAcylation levels between the samples from cells 
treated with or without 10 µM NAG were apparent two hours after incubation (Figure 
3.1B), but the total level of O-GlcNAcylated proteins were highest 24 hours after 
incubation. The size of the NAG induced O-GlcNAc immunoreactive bands were 
approximately 55, 60, 80, 90, 145, 155, 250 kDa.  
The general O-GlcNAc antibodies CTD 110.6 and RL2 detect subsets of O-
GlcNAcylated proteins giving a view of the overall O-GlcNAcylation, but do not 
detect all possible O-GlcNAcylated proteins. Both antibodies preferentially recognize 
high molecular weight proteins. CTD 110.6 was used in the immunoblot experiments 
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in figure 1. We also performed parallel blots using RL2 which detected a similar 
pattern of immunoreacitve bands (data not shown).  
 
Fig. 3.1. Concentration and time dependent effects of NAG-thiazoline on O-
GlcNAcylation in HUVEC 
A. HUVEC were treated with 0, 10, 20 and 40 µM NAG for 24 hours. Whole cell 
extract was prepared and  22 μg protein pr. lane was separated by SDS‐PAGE (4‐
20 % gel) followed by western blotting using the monoclonal antibody CTD 110.6 
which detects a subset of O‐GlcNAcylated proteins. β‐Actin was used as a loading 
control. B. HUVEC were incubated with 10 µM NAG for 2, 6 and 24 hours.  Whole 
cell extract was prepared and the protein concentration was adjusted to 0.9 µg/µl, 
before N‐and O‐GlcNAcylated proteins were precipitated from 500 µl lysate using 
sWGA. The same amount of samples were loaded in each lane and analyzed by 
SDS‐PAGE (4‐20 % gel) and western blotting using CTD 110.6. The antibody OGT 
was included as a positive control.  
 
3.2 Effects of glucose on the level of protein O-
GlcNAcylation in HUVEC  
To examine the time-effects of  hyperglycaemia on the general level of O-
GlcNAcylated proteins in HUVEC, cells were grown in 5 or 25 mM D-glucose and 
harvested 4, 24, 48 and 72 hours after incubation. The media was changed every 24 
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hour to avoid secondary autocrine effects of hyperglycaemia and to maintain the 
glucose concentration. Whole cell lysates were analyzed by immunoblotting.  
The total level of O-GlcNAcylation increased with time, but this effect was observed 
both in the normo- and hyperglycaemia treated cells (Figure 3.2A). The difference 
between the normo- and hyperglycaemia treated cells was most apparent 4 hours after 
incubation. We observed the appearance of three bands of approximately 60, 80 and 
220 kDa in cells treated with 25 mM D-glucose for 4 hours. However, the bands were 
visible both in cells treated with 5 mM and 25 mM D-glucose when incubated for 48 
and 72 hours.  
Next, we examined the specificity of the immunoreactive bands using free N-
acetylglucosamine (GlcNAc) as a competitor of CTD 110.6. The CTD 110.6 
antibody was preincubated with 0.5 M GlcNAc for 5 minutes on ice before 
incubation with the western blot. Immunoreactive bands of approximately (25, 50, 
60, 80, 90, 150, 250 kDa were specifically lost, indicating that the majority of the 
immunoreactive bands were O-GlcNAcylated proteins (Figure 3.2B).  
Diabetes is characterized by chronic hyperglycaemia. Several reports studying effects 
of hyperglycaemia in endothelial cells incubate the cells for 48 hours or longer (85-
93). To study the effects of D-glucose on protein O-GlcNAcylation levels, HUVEC 
treated with 1, 2.5, 5, and 25 mM D-glucose for 48 hours were lysed, and sWGA 
precipitation were used to enrich for N-and O-GlcNAc modified proteins. The 
intensity of an O-GlcNAcylated immunoreactive band of approximate 70 kDa was 
highest in samples treated with 1 mM compared to 2.5 mM D-glucose. Bands of 
approximately 100 kDa, 160 kDa and 170 kDa were nearly absent at 1 mM D-
glucose, but increased from 2.5 to 25 mM D-glucose treatment (Figure 3.2C). We 
also observed a more distinct increase in O-GlcNAcylation from 5 to 25 mM D-
glucose compared with whole cell lysates in Figure 3.2A, indicating an advantage 
using sWGA.  
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Fig. 3. 2. Time and dose effects of glucose on the level of protein O-
GlcNAcylation 
A. HUVEC were incubated with 5 or 25 mM D‐glucose for 4, 24, 48 or 72 hours. 
Whole cell lysates were made and samples, (18 μg protein/lane) were analyzed by 
SDS‐PAGE (7.5 % gel) and western blotting using the monoclonal antibody RL2 
which detect a subset of O‐GlcNAcylated proteins. β‐Actin was used as a loading 
control. B. HUVEC were incubated with 25 mM D‐glucose for 48 hours. Whole cell 
lysates were prepared and samples (15 µg protein/lane) analyzed by SDS‐PAGE (4‐
20 % gel) and western blotting. 0.5 M N‐acetylglucosamine (GlcNAc) (+) was used 
as a competitor of CTD 110.6, and O‐GlcNAcylated proteins were specifically lost 
(+) due to the competition. C. HUVEC were incubated with 1, 2.5, 5 or 25 mM D‐
glucose for 48 hours. Whole cell lysates were prepared and the protein 
concentration adjusted to 0.7 µg/µl before N‐and O‐GlcNAcylated proteins were 
precipitated from 500 µl lysate using sWGA. The same amount of samples were 
loaded in each lane, and analyzed by SDS‐PAGE (4‐20 % gel) and western blotting 
with CTD 110.6. The antibody OGT was used as a positive control.  
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3.3 Effects of hyperglycaemia on LXRβ O-GlcNAcylation 
It has recently been suggested that LXR is a glucose sensor in human HepG2 cells 
and in vivo in mouse liver (60). The direct binding of the hydrophilic glucose 
molecule to the hydrophobic pocket of LXR reported by Mitro et al (60) is surprising. 
The hydrophilic nature of the glucose molecule indicates that glucose rather may 
affect LXR indirectly via downstream glucose signalling pathways. LXRα/β has 
several potential O-GlcNAcylated sites as identified by YinOYang (1) search 
(Appendix A and B). For this reason we wondered whether LXR is a target for O-
GlcNAc modification. HUVEC were incubated with 1, 2.5, 5 or 25 mM D-glucose 
for 48 hours. Whole cell lysates were made and sWGA was used to precipitate O-and 
N-GlcNAcylated proteins. Western blot was analyzed using the LXR antibody R20. 
The immunoreactive band in Figure 3.3A indicates that LXR are GlcNAcylated 
(Figure 3A). The antibody R20 detects both LXRα and LXRβ. In the sWGA samples 
we detected only one immunoreactive band of about 60 kDa (Figure 3A). In order to 
reveal the LXR isoform, LXRβ IP and LXRα IP were carried out. LXRα and LXRβ 
move differently in SDS-PAGE. The predicted size of LXRα and LXRβ 
immunoreactive band is approximately 50 kDa. However, we observed that LXRβ is 
constantly about 60 kDa in several cell types. The LXRβ IP (Figure 3.3C), revealed 
an immunoreactive band of the same size as the immunoreactive band observed in the 
sWGA samples in Figure 3.3A, indicating that the immunoreactive band in the 
sWGA samples represent LXRβ. LXRα IP revealed a band of 50 kDa, but the same 
size as the heavy chain makes it difficult to interpret (data not shown). It is reasonable 
to suppose that the concentration of LXRα is low in HUVEC compared with LXRβ, 
since it is reported that LXRα mainly is expressed in the liver, adipose tissue and 
macrophages, whereas LXRβ is ubiquitously expressed (54). Furthermore, 
preliminary data from human HepG2 cells and THP-1 cells indicate that LXRβ is 
target for O-GlcNAcylation.  
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The intensity of LXRβ in the sWGA samples (Figure 3.3A) increases with the D-
glucose concentration indicating that GlcNAcylation of LXRβ increases with 
increasing D-glucose concentrations.   
HUVEC were treated with NAG-thiazoline for 2, 6 or 24 hours to inhibit O-
GlcNAcase and thereby promoting O-GlcNAc modifications. LXR is a nuclear 
hormone receptor, and mainly expressed in the nucleus. Nuclear extracts were 
prepared, O- and N-GlcNAcylated proteins were immunoprecipitated using sWGA, 
and samples were analyzed by western blotting. The intensity of LXRβ 
immunoreactive bands increased with NAG-thiazoline treatment in a time dependent 
manner (Figure 3.3C).   
To further examine whether LXRβ is O-GlcNAcylated, we IPed LXRβ and incubated 
the western blot with RL2 monoclonal antibody, but did this not reveal 
immunoreactive bands (data not shown). We also immunoprecipitated O-
GlcNAcylated proteins using RL2 antibody, but again did not observe LXRβ 
immunoreactive band when incubating the blot with the LXRβ specific antibody. 
However, Flag tagged LXRβ transfected in HepG2 was used as a positive control and 
the transfected LXRβ was detected by the RL2 antibody and LXRβ, indicating that 
LXRβ is a target for O-GlcNAcylation (data not shown). 
To study whether LXRβ protein level is regulated by different D-glucose 
concentrations in HUVEC, cells were incubated with 1 mM, 2.5 mM, 5 mM or 25 
mM for 48 hours. Whole cell lysates were analyzed by SDS-PAGE and western 
blotting. Figure 3.3A shows that LXRβ protein level is not regulated by different D-
glucose concentrations when incubated for 48 hours.  
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Fig. 3.3. Effects of glucose on O-GlcNAcylation of LXR  
A. HUVEC were treated with 1, 2.5, 5 or 25 mM D‐glucose for 48 hours. Whole cell 
lysates were prepared and the protein concentration adjusted to 0.7 µg/µl before 
N‐and O‐GlcNAcylated proteins were precipitated from 500 µl lysate using sWGA. 
The same amount of samples were loaded in each lane, and analyzed by SDS‐
PAGE (4‐20 % gel) and western blotting using the antibody R20 detecting LXRα/β. 
OGT was included as a positive control. B. HUVEC were incubated with 10 µM 
NAG and harvested 2, 6 and 24 hours after incubation. Nuclear extracts were 
made, and the protein concentrations were adjusted to 0.9 µg/µl, before N‐and O‐
GlcNAcylated proteins were precipitated from 500 µl lysate using sWGA. The same 
amount of samples were loaded in each lane and analyzed by SDS‐PAGE and 
western blotting using a specific antibody against LXRβ. The antibody OGT was 
included as a positive control. C. HUVEC were treated with 1, 2.5, 5 or 25 mM D‐
glucose for 48 hours. Whole cell lysates were prepared and the protein 
concentration adjusted to 0.7 µg/µl. LXRβ was immunoprecipitated from 500 µl 
lysate and the same amount of samples were loaded into each lane and analyzed 
by SDS‐PAGE and western blotting using a specific antibody against LXRβ. 
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3.4 Effects of glucose on Id1 and Id3 protein expression 
and O-GlcNAcylation 
D-glucose is reported to affect the expression of Id proteins, but the response differ 
according to cell type (65;70). Whether D-glucose induces the expression of Id 
proteins in HUVEC have not previously been examined. In our experiments, Id2 was 
not detected in HUVEC and glucose failed to induce the Id2 protein expression (data 
not shown). In the following experiments we thus focused on Id1 and Id3 proteins.  
Preliminary experiments in the present study indicated that hyperglycaemia for 4-24 
hours did not regulate the expression of Id1 and Id3 proteins (data not shown).  
It is reported that agents (eg. D-glucose, TSH) induce a biphasic pattern of Id 
expression (70;94), and it is suggested that Id proteins could regulate rapid as well as 
long term responses to changes in glucose concentrations.  
To study the effects of chronic D-glucose exposure on Id1 and Id3 protein expression 
in HUVEC, cells were treated with 1, 2.5, 5 or 25 mM D-glucose for 48 hours. The 
Id1 immunoreactive bands observed did not differ in intensity, indicating that Id1 
protein levels were not affected by different D-glucose concentrations at this time 
point (Figure 3.4A). In contrast, the Id3 protein levels increased with increasing D-
glucose concentrations (Figure 3.4A).  
We incubated cells with different NAG-thiazoline concentrations for 24 hours in 
order to promote O-GlcNAcylation. Prolonged treatment with the O-GlcNAcase 
inhibitor PUGNAc is not toxic to cells, but treatment above 18 hours do not result in 
additional increase in O-GlcNAcylation (48). Whole cell lysates were analyzed by 
SDS-PAGE and western blotting using Id1 and Id3 specific antibodies. The Id1 
protein levels were not affected by NAG-thiazoline treatment as indicated by the 
same intensity of the immunoreactive bands (Figure 3.4B). However, the expression 
of Id3 protein increased with increasing NAG-thiazoline concentrations (Figure 
3.4B).  
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YinOYang (1) search for potential Id O-GlcNAcylation sites suggests that Id1 has 5 
potential O-GlcNAc sites, including one high score site at serine 16 and one site at 
serine 130 predicted to be target for both phosphorylation and O-GlcNAcylation 
(Appendix C). In contrast, Id3 has only one low score potential O-GlcNAc site at 
serine 116 (Appendix D).  
In order to study whether Id1 protein are O-GlcNAcylated, HUVEC were incubated 
with 1, 2.5 , 5 or 25 mM D-glucose for 48 hours, whole cell lysates were prepared 
and Id1 was immunoprecipitated. The samples were analyzed by immunoblotting 
using the monoclonal antibody CTD 110.6. We detected bands of approximately 15 
and 20 kDa (Figure 3.4C). The bands differed in intensity with the strongest intensity 
at 2.5 mM D-glucose and the weakest intensity at 25 mM D-glucose. The blots were 
stripped and reprobed with a polyclonal antibody against Id1, revealing bands of the 
same size (Figure 3.4C).   
The level of immunoprecipitated Id1 differed between the samples (Figure 4C), with 
the highest level at 2.5 mM D-glucose and the lowest level at 25 mM D-glucose 
coinciding with the Id1 O-GlcNAc levels. This phenomenon was seen in different 
experiments and time points.  
RL2 monoclonal antibody was used to immunoprecipitate O-GlcNAcylated proteins. 
Cells treated with 5 and 25 mM D-glucose for 48 hours was lysed, and RL2 
immunoprecipitated proteins were analyzed by immunoblotting. Immunoblot of RL2-
IP samples with a polyclonal Id1 antibody revealed an immunoreactive band of 
approximately 15 kDa, suggesting that Id1 is O-GlcNAcylated (Figure 3.4D). The 
total Id1 protein levels increased from 5 mM D-glucose to 25 mM D-glucose, 
indicating that hyperglycaemic conditions increase the level of O-GlcNAc 
modifications on Id1 protein. The blot was reprobed with RL2 antibody and Figure 
3.4D show an increase in the level of O-GlcNAcylated proteins when exposed to 
hyperglycaemia. 
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Fig. 3.4. Effects of glucose on Id1 and Id3 protein expression and O-
GlcNAcylation 
A. HUVEC were incubated with 5 or 25 mM D‐glucose for 48 hours and B.  0, 10, 
20 and 40 µM NAG for 24 hours. Whole cell lysates were prepared and 22.5 μg 
protein were loaded into each lane, separated by SDS‐PAGE (4.20 % gel) and 
analyzed by immunoblotting using polyclonal antibodies against Id1 and Id3 
proteins. β‐Actin was used as a loading control. C. HUVEC were incubated with 1, 
2.5, 5 or 25 mM D‐glucose for 48 hours, whole cell lysates were prepared and the 
protein concentrations adjusted to 1.1 µg/µl. Id1 proteins were 
immunoprecipitated from 500 µl lysate. The same amount of samples were 
loaded into each lane and analyzed by immunoblotting (4‐20 % gel) using the 
monoclonal antibody CTD 110.6 against O‐GlcNAcylated proteins. The membrane 
was stripped and reprobed with a polyclonal antibody against Id1. D. HUVEC were 
incubated with 5 mM or 25 mM D‐glucose for 48 hours, whole cell lysates were 
prepared and the protein concentrations adjusted to 0.7 µg/µl. O‐GlcNAcylated 
proteins were immunoprecipitated from 500 µl lysate using the RL2 antibody. The 
samples were analyzed by SDS‐Page (4‐20 % gel) and western blotting using Id1 
polyclonal antibody. The membrane was stripped and reprobed with the 
monoclonal antibody RL2 and a light chain specific secondary antibody.  
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4. Discussion 
4.1 Concentration and time dependent effects of NAG-
thiazoline on O-GlcNAcylation 
PUGNAc and NAG-thiazoline are used to inhibit O-GlcNAcase, thus promoting O-
GlcNAc modification on intracellular proteins. NAG-thiazoline is not commercially 
available, and the optimal concentration in HUVEC is not known, but it is reported to 
be more potent than PUGNAc (49). 
We found that 10 μM NAG-thiazoline is sufficient to promote O-GlcNAcylation in 
HUVEC. This is 10 fold less than the optimal dose of PUGNAc used to promote O-
GlcNAc modification in several different cell types (46;81-84). In adipocytes 
incubated with varying concentrations of PUGNAc for 12 hours, the maximal 
increase in O-GlcNAc levels appeared at 100 μM PUGNAc, and no further increase 
in O-GlcNAc level was seen in cells treated with higher concentrations (95). 
O-GlcNAcylation is a dynamic process. We investigated O-GlcNAc levels in 
HUVEC treated with 10 μM NAG-thiazoline at different time points. The level of O-
GlcNAc modifications increased significantly with time. This is comparable with 
other studies using PUGNAc. Adipocytes incubated with 100 μM PUGNAc 
displayed a modest increase in O-GlcNAc levels in cells treated for 6 hours, whereas 
cells treated for 12 hours showed a considerable increase in O-GlcNAc levels (95). 
A single protein may show different optimal time for maximal O-GlcNAcylation as 
compared to overall O-GlcNAcylation level. PUGNAc treatment in SH-SY5Y 
neuroblastoma cells caused an overall increase in O-GlcNAcylation level after 60 
minutes of treatment, whereas maximal O-GlcNAc modification of Akt1 occurred 30 
minutes after treatment (96). In sWGA samples in Figure 1B, OGT was used as a 
positive control. The maximal O-GlcNAcylation of OGT appeared 2 hours after 
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NAG-thiazoline treatment, whereas the maximal overall O-GlcNAcylation appeared 
24 hours after treatment.  
4.2 Effects of glucose on the level of protein O-
GlcNAcylation in HUVEC  
Hyperglycaemia is associated with endothelial dysfunction and increased risk of 
micro- and macrovascular complications. Increased levels of protein O-
GlcNAcylation may be a molecular mechanism by which hyperglycaemia induce 
endothelial dysfunction and thus contribute to the pathogenesis of vascular 
complications.  
Hyperglycaemia is shown to increase the total level of O-GlcNAcylated proteins in 
different cell types; Rin-m5f cells (rat pancreatic β-cell line), HepG2 cells and rat 
smooth muscle cells (72;97;98). One specific aim of this study was to elucidate 
whether hyperglycaemia (25 mM) increases the level of O-GlcNAcylated proteins in 
HUVEC, and we found in agreement with other reports that hyperglycaemia 
increases the level of O-GlcNAcylated proteins in a time dependent manner. 
However, we also observed increases in levels of O-GlcNAc modified proteins in 
normoglycaemic (5 mM) treated cells (Figure 3.2A), indicating time-in-culture 
effects.  
In the literature, we have observed that the normoglycaemia (5 mM) control samples 
for each time point seldom are presented (81;96;97;99). We have not found reports 
presenting total protein O-GlcNAcylation levels of glucose treatment for more than 
24 hours with normoglycaemia control samples. Taylor et al found no increase in 
total O-GlcNAcylation in HepG2 cells treated with 5 mM D-glucose for 1- 24 hours 
(98).  
Before incubation with different D-glucose concentrations, the MCDB medium 
containing 5 mM D-glucose was changed to RPMI 1640 medium added the same 
concentration of D-glucose and FBS (7 %), but lacking the growth factors and 
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antibiotics. The next morning, the cells were incubated with RPMI 1640 containing 
different concentrations of D-glucose. The medium was replaced every 24 hours in 
order to maintain the D-glucose concentration and to avoid any secondary autocrine 
effects of glucose. We do not know the reason for the increase in O-GlcNAcylation in 
the 5 mM control samples with time in culture. All cells were treated identically, 
except from incubation with different D-glucose concentrations. We can not, 
however, exclude the possibility that other factors than glucose may have induced the 
increase in O-GlcNAcylation seen with time. 
HUVEC is sensible to serum starvation, especially when lasting for more than 24 
hours (100). For longer experiments, the absence of growth factors triggers apoptosis. 
In our experiments, we used 7 % FBS. FBS is a complex mixture containing, besides 
growth factors, a variety of proteins, lipids, glucose, salts, minerals, amino acids, 
growth hormones, trace elements and other factors not fully identified 
(http:/www.sigmaaldrich.com). The hexosamine signalling pathway is a nutrient 
signalling pathway (28;29;101) and it is possible that constituents in the FBS may 
have affected the level of O-GlcNAcylation. The boost of FBS each 24 hour may 
have triggered O-GlcNAcylation with time, possibly via activation or increased level 
of GFAT or OGT.   
In order to examine whether the immunoreactive bands induced by hyperglycaemia 
were specific, HUVEC were subject for competition experiments with free GlcNAc. 
The majority of the immunoreactive bands (25, 50, 60, 80, 90, 150, 250 kDa) were 
specifically lost due to the competition. The sizes of the immunoreactive bands are 
comparable with the NAG-thiazoline induced immunoreactive bands in Figure 1.  
A number of studies have reported that acute activation of O-GlcNAc formation is a 
cytoprotective stress response. However, sustained increases in O-GlcNAc have been 
associated with the pathogenesis of diabetes and diabetic complications (102).  
When studying effects of hyperglycaemia in endothelial cells, the literature indicates 
distinct effects when cells are treated with hyperglycaemia for 48 hours and above. It 
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is shown that hyperglycaemia induced marked increase in O-GlcNAcylation of IRS-
1, IRS-2 and p85, resulting in insulin resistance in human coronary artery endothelial 
cells (HCAEC) incubated for 72 hours (52). Du et al (87) showed that 
hyperglycaemia for 48 hours in BAEC increased O-GlcNAcylation of SP1. 
To study the effects of different glucose concentrations on the level of O-
GlcNAcylated proteins, HUVEC were incubated with 1, 2.5, 5 or 25 mM D-glucose 
in RPMI 1640 medium for 48 hours. Succynilated WGA was used to enrich the 
lysates of GlcNAcylated proteins. Figure 3.2C show that increased concentration of 
D-glucose induced an increased level of O-GlcNAcylation. The difference in O-
GlcNAcylation between normo- (5 mM) and hyperglycaemia (25 mM) treated cells 
(Figure 3.2C) were more distinct than the increase observed between the 48 hour 
treated normo- and hyperglycaemia treated cells in Figure 3.2A, indicating an 
advantages to use sWGA.  
In the same experiment (Figure 3.2C), we observed that a 70 kDa immunoreactive 
band displayed increased intensity in both hypo- and hyperglycaemia treated cells. 
An immunoreactive band of approximately 100 kDa and two high molecular bands 
were nearly absent in the samples from cell treated with 1 mM D-glucose (Figure 
3.2C). Hypoglycaemia is a stressful situation, and stress is known to induce O-
GlcNAc modifications and promote cell survival. In glucose sensitive cells (liver 
cells and neuroblastoma cells), glucose deprivation induced a significant increase in 
the level of O-GlcNAcylated proteins 6-24 hours after deprivation (98;99).  
Several of the O-GlcNAc targets induced were distinct from those modified in 
response to hyperglycaemia. Cells incubated with 1 mM D-glucose did however, not 
show a marked stress induced increase in O-GlcNAcylation. We did not observe 
induction of unique immunoreactive bands or increased level of O-GlcNAcylation, 
indicating that the effect was not a general stress response. It is not, however, 
unlikely that individual proteins may show different sensitivities to stress. The level 
of confluence is also observed to influence the effect of glucose deprivation. Taylor 
et al observed that 70 % confluence was optimal for promoting glucose deprivation in 
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HepG2 cells. Under- and over- confluent cells displayed a reduced effect (98). In our 
experiments, the cells were 80-100 % confluent as observed in the microscope. 
It has been suggested that hyperglycaemic peaks may play a significant role in the 
pathogenesis of vascular diabetic complications (15;103). Levels of postprandial 
plasma glucose appear to be a stronger predictor of cardiovascular disease than stable 
elevated plasma glucose (104). Intermittent treatment with hyperglycaemia (24 hour 
cycles) for 7-14 days is shown to induce a greater increase in the levels of the 
adhesion molecules ICAM-1, VCAM-1 and E-selectin than stable hyperglycaemia 
(105). For future studies, intermittent glucose load on the level of O-GlcNAcylated 
proteins will be an interesting subject for examination.  
One future aim is to identify glucose or NAG-thiazoline induced O-GlcNAcylated 
proteins by mass spectrometry. PNGase F treatment (96) will remove all N-linked 
GlcNAcylations and O-GlcNAcylated proteins are immunoprecipitated using sWGA. 
Immunoactive bands on western blot will than be analyzed by mass spectrometry.  
4.3 Effects of glucose on LXR O-GlcNAcylation 
LXR are nuclear receptors that coordinate carbohydrate and lipid metabolism. 
Oxysterols are known LXR ligands, but recently it was reported that LXR activity 
was regulated by direct binding of D-glucose (60) and D-glucose was able to induce 
the expression of the LXR target gene ABCA1 (60). 
ABCA1 promotes the efflux of free cholesterol and phospholipids from cells to lipid-
poor apolipoproteins A-1 (apoA-1) to generate nascent High density lipoproteins 
(HDL)-particles. LXR function in endothelial cells has not been extensively studied. 
It is reported that ABCA1 is a LXR target gene in HUVEC involved in reverse 
cholesterol transport to Apo-A1 in the vascular lumen. ABCA1 in HUVEC is up-
regulated by LDL (55) and down-regulated by oxLDL (56). Endothelial cells express 
oxLDL receptors. Since endothelial cells rarely accumulate lipids, it was 
hypothesized that oxLDL-induced down-regulation of ABCA1 leads to efflux of 
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cholesterol to the subendothelial space via caveolae. The changed transport route may 
lead to subendothelial deposition of lipids and plaque formation in the intima (56).  
The direct binding of the hydrophilic glucose molecule to the hydrophobic pocket of 
LXR reported by Mitro et al (60) is surprising. The hydrophilic nature of the glucose 
molecule indicates that glucose rather may affect LXR indirectly via downstream 
glucose signalling pathways. Earlier studies have shown that LXR are 
posttranslationally modified by phosphorylation (106), acetylation (107) and 
sumoylation (108). 
Both, LXRα and -β have several potential O-GlcNAcylation sites (Appendix A and 
B), and O-GlcNAcylation may be a mechanism by which LXR is posttranslationally 
modified and affected by glucose. The predicted size of LXRα and LXRβ 
immunoreactive band is approximately 50 kDa. However, we observed that LXRβ is 
constantly about 60 kDa in several cell types. LXRβ IP in HUVEC revealed an 
immunoreactive band of about 60 kDa, indicating that the immunoreactive band of 
about 60 kDa detected by the antibody R20 in the sWGA samples is LXRβ. LXRα 
immunoreactive bands of 50 kDa were not detected by the R20 antibody in the 
sWGA samples. This is probably due to low concentration of LXRα in HUVEC.  
To further study whether LXRβ is O-GlcNAcylated, LXRβ was immunoprecipitated 
from whole cell extracts and analyzed by western blotting using the antibodies RL2 
or CTD 110.6. However, LXRβ was not detected. The samples were resuspended in 
80 µl loading dye in order to be able to analyze parallel gels, leading to lower LXR 
concentration, and this may be one possible explanation for the negative results. Flag 
tagged LXRβ transfected in HepG2 cells was used as a positive control, and 
transfected flag tagged LXRβ from HepG2 cells was detected by the RL2 antibody 
(data not shown). This indicates that LXRβ is a potential target for O-GlcNAcylation. 
The difference seen may be due to different cell types or higher protein concentration 
in the transfected cells.  
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To further study whether LXRβ is a target for O-GlcNAcylated in HUVEC, it may be 
necessary to overexpress LXR in order to increase the protein concentration and to 
analyze the whole IP on one gel. Immunoprecipitation from nuclear lysates or 
upscaling the IP may further increase the concentration. To confirm the results and 
identify O-GlcNAcylation site, mass spectrometric analysis will be performed.  
4.4 Effects of glucose on Id1 and Id3 protein expression 
and O-GlcNAcylation 
D-glucose is reported to affect the expression of Id proteins, but the response differ 
according to cell type (65;70). Hyperglycaemia is shown to induce Id1 mRNA and 
Id1 protein in pancreatic β-cells. Hyperglycaemia also induce the level of Id1 mRNA 
in CaCo-2 cells, but has no effect on the level of Id1 and Id3 mRNA in BC3H1 or 
HepG2 cells (70). In murine J774.2 macrophages hyperglycaemia induce an 
increased level of Id2 protein (75). 
Effects of glucose on Id proteins in HUVEC have not previously been studied. Our 
data indicates that Id3 is, in contrast to Id1, regulated by different D-glucose 
concentrations when incubated for 48 hours. Even though it has been demonstrated 
that Id1 and Id3 have similar promoter sequence and the pattern of Id1 expression 
most closely resembles that of Id3, it is reported that they are regulated differently by 
Fluvastatin (109), a 3-hydroxyl-3-methylglutaryl-coenzyme A (HMG-CoA) 
reductase inhibitor. Statins is used to lower cholesterol levels in patients (110), and it 
can also regulate angiogenesis (109). 
HUVEC can survive in serum-free medium for up to 12 hours without losing their 
phenotypic features. For longer experiments, in particular those lasting more than 24 
hours, the absence of growth factors triggers apoptosis (100). We replaced the 
endothelial basal medium (MCDB131) with RPMI1640 medium during experiments. 
When the cells were grown in RPMI with low serum, they appeared to grow 
somewhat differently than when the serum was maintained at the same level as 
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during culturing. We thus kept the FBS concentration at 7 % also during experiments, 
and this may have confounded the results. Serum is shown to induce Id1 and Id2 
mRNA (61;111), and Id3 was first identified as a serum-inducible gene (65). 
Preliminary data performed in this study indicates that Id1 protein may be regulated 
by glucose when grown in 2 % serum. The experiment is however performed only 
once, so conclusions can not yet be drawn.  
Glucose has been shown to induce a biphasic increase in Id1 and Id3 mRNA and Id1 
protein, with highest expression 30 minutes after addition of D-glucose. Thereafter, 
the concentration decreased for 2 hours, before steadily increasing for 24 hours (70). 
Based on the biphasic time pattern, it is suggested that Id proteins could regulate 
rapid as well as long term responses to changes in D-glucose concentrations. We 
incubated the cells with D-glucose for 48 hours, focusing on chronic hyperglycaemia. 
We found that Id1 protein did not seem to be regulated by chronic hyperglycaemia in 
HUVEC, but we can not, however, rule out that Id1 may be regulated by acute (15 
minutes-4 hours) hyperglycaemia. It is also not known whether intermittent 
hyperglycaemia affects Id proteins. Fasting and refeeding is reported to regulate Id 
expression in rainbow trout (112), and it would be interesting to study the effects of 
intermittent hyperglycaemia on the level of Id proteins in human endothelial cells.  
Our data indicates that Id3 protein levels are up-regulated by increasing NAG-
thiazoline concentrations, indicating that O-GlcNAcylation may regulate Id3 protein 
expression. Several transcription factors are known to be O-GlcNAcylated (113). 
Hyperglycaemia is shown to induce O-GlcNAcylation of the ubiquitous transcription 
factor Sp1 (84;87). Sp1 is shown to regulate Id1 (114) and Id4 (115). In order to 
further elucidate whether Id3 is regulated via the hexosamine signalling pathway, 
more studies are needed. GFAT requires glutamine for normal function, and 
incubating cells with medium lacking glutamine, incubate cells with the GFAT 
inhibitor DON, or incubate cells with glucosamine which is acting downstream of 
GFAT, may establish our findings.  
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Preliminary experiments in our group indicate that Id2 is target for O-GlcNAcylation 
(76). To study whether Id1 is target of O-GlcNAcylation in HUVEC, cells were 
incubated with different D-glucose concentrations, whole cell lysates were prepared, 
Id1 or O-GlcNAcylated protein were immunoprecipitated, and the samples analyzed 
by immunoblotting. A 15 kDa CTD110.6 immunoreactive band was detected in Id1 
immunoprecipitates and Id1 was detected in RL2 immunoprecipitates, indicating that 
Id1 is target for O-GlcNAcylation. We are, however, not able to conclude whether D-
glucose up-regulates O-GlcNAcylation of Id1, because the level of 
immunoprecipitated proteins differed between the samples. The IPs were carried out 
from lysates containing the same amount of proteins. We do not know why the level 
of immunoprecipitated proteins differed between the samples. The Id1 polyclonal 
antibody is raised against a peptide mapping to the C-terminus of Id protein. Id1 has 
two potential O-GlcNAc sites in the C-terminus, and we speculate that O-
GlcNAcylation of Id1 may interfere with the binding of the antibody to Id1.  
Formation of new blood vessels into an atherosclerotic plaque is associated with 
increased risk of fatal outcome. The immature vessels leak erythrocytes (cholesterol 
rich membranes) and inflammatory cells into the core of the plaque. Several new 
vessels increase the risk of intra plaque haemorrhages and rupture (116;117). Intra 
plaque haemorrhage is shown to be increased in plaques from diabetic patients (71). 
Activated T-cells, macrophages and mast cells in the atherosclerotic plaque produce 
proangiogenic molecules such as VEGF and IL8 (116). VEGF is shown to induce the 
expression of Id1 and Id3 in HUVEC (74). There are similarities between vessels of 
tumours and plaque vessels. Both, tumours and plaques require oxygen and thus new 
blood vessels when the size limits the diffusion of oxygen (116). Id proteins are 
thought to facilitate angiogenesis in tumours (67;69). It is shown that overexpression 
of Id can induce proliferation, activation (increased the expression of ICAM-1 and E-
selectin) and angiogenic processes in HUVEC (transmigration, expression of matrix 
metalloproteinases-2 and –9, and tube formation) (74). The effects of hyperglycaemia 
on angiogenesis are not fully understood (72). Both, up- and down regulation of 
angiogenesis in different tissues have been reported as a consequence of 
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hyperglycaemia. It would be interesting to study whether hexosamine induced up-
regulation of Id3 or O-GlcNAcylation of Id1 may affect angiogenic processes in 
HUVEC.  
4.5 HUVEC  
Primary cells are more heterogeneous than cell lines. The differences we found in 
some of the experiments may reflect variations in lifestyle and genetic constituents 
between the individual HUVEC donors. The cells were grown under the same culture 
conditions for up to 3 weeks prior to each experiment, and this will probably reduce 
potential differences. 
Blood vessels and the function of the endothelial cells vary according to location 
(5;118). The expression of GFAT is for example shown to vary between small and 
medium sized vessels of various organs (35), indicating differences in O-
GlcNAcylation between different vascular beds).  
Specific arterial and venous gene expression pattern have been identified (118). 
HUVEC are endothelial cells from a vein transporting arterial blood from the 
placenta to the foetus. Endothelial cells isolated from umbilical cords are readily 
available and a valuable source to study glucose induced endothelial dysfunction, but 
one should bear in mind that their properties may differ from other types of 
endothelial cells (21;80;100;118).  
To my knowledge, O-GlcNAcylation has not been studied in HUVEC. One 
advantage using HUVEC is that our lab has access to human umbilical cords and has 
long expertise in isolating HUVEC. Increasing evidence show however, that 
endothelial cells isolated from HUVEC differ in their responses to agonists in 
comparison to arterial endothelial cells (119). HUVEC thus has its limitations as a 
model system when studying glucose induced endothelial dysfunction as an early 
event in atherosclerosis. Experiments in HUVEC should be followed by experiments 
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in the less available and more expensive human artery endothelial cells (HAEC) or 
human coronary artery endothelial cells (HCAEC).  
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5. Conclusions 
The results of this study indicate that:  
• The O-GlcNAcase inhibitor NAG-thiazoline is 10 times more potent than 
PUGNAc on protein O-GlcNAcylation in HUVEC, and 10 µM is sufficient to 
induce an increase in overall O-GlcNAcylation in HUVEC.  
• Hyperglycaemia increases protein O-GlcNAcylation in HUVEC in a time 
dependent manner. However, because we also observed an increase in O-
GlcNAcylation in the normoglycaemia treated control samples with time, firm 
conclusions can not yet be drawn. It is necessary to optimalise the culturing 
conditions during experiments, allowing for serum free conditions. 
Succinylated WGA to precipitate GlcNAcylated proteins prior to SDS-PAGE 
and western blot analysis reveal a more distinct difference in total O-
GlcNAcylation between cells cultured in normo- versus high glycaemic 
conditions.  
• Id1 protein is a target for O-GlcNAcylation and Id1 expression is not regulated 
by chronic D-glucose exposure in HUVEC. This is in contrast to Id3. 
However, the FBS concentration used during experiments may have 
confounded the observed results and further studies are needed in order to 
make firm conclusions.  
• LXRβ is a promising candidate for O-GlcNAcylation. Our data indicates that 
LXRβ is target for GlcNAcylation as indicated by sWGA precipitation 
experiments, but more studies are needed in order to conclude whether LXRβ 
is a target for GlcNAcylation and to identify the nature of the GlcNacylation.  
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7. Tables 
Table 1. Complete MCDB culture medium  
Ingredients Final concentration 
EBM-media M-8537 (MCDB-
131 medium) 
Powder for 1000 ml 
Epidermal growth factor (EGF) 10 ng/ml 
Fibroblast growth factor (FGF) 1 ng/ml 
Hydrocortisone 1 µg/ml 
Fungisone 250 ng/ml            
Gentamycin 50 µg/ml                    
Foetal bovine serum (FBS) 
(heat inactivated) 
7 %   
The D-glucose concentration in baseline EBM is 5 mM.  
 
Table 2. Transporting buffer 
Ingredients Final concentration 
1x PBS (sterile) 1000 ml 
Streptomycin sulphate                  50 mg/l 
Stored at 4oC 
 
Table 3. 10x PBS, pH 6.8                                                                                                                       
Ingredients Final concentration 
NaH2PO4 x 2H2O 4,832 mM   
KH2PO4 1,937 mM 
NaCl 1,454 M 
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Table 4. RIPA-buffer 
Ingredients Final concentration 
NP-40  1 % 
SDS 0.1 % 
NaCl 0.15 M 
Tris-HCl 50 mM 
Na-deoxycholate 0.5 %  
AEBSF 1 mM                           
NAG-thiazoline 1 µM                          
Protease inhibitors 1 tablet pr. 10 ml 
ALLN 1/100 – 1/400 µl 
 
Table 5. Loading buffer (1x) 
Ingredients Final concentration 
Tris pH 6.8  40 mM 
SDS 0.8 % 
Glycerol 4 % 
Bromphenol Blue  0.025 % 
 
Table 6. Lysis buffer 
Ingredients Final concentration 
NP-40 0.2 %                               
1x PBS 96,68 %                      
DTT 1 mM 
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AEBSF 1 mM                           
NAG-thiazoline 1 µM                          
Protease inhibitors 1 tablet pr. 10 ml 
ALLN 1/100 – 1/400 µl 
NaF 50 mM                          
NaPPi 0.01 M                            
N3VO4 0.001 M   
 
Table 7. NE2 lysis buffer  
Ingredients Final concentration 
Hepes pH 7.9 20 mM                  
MgCl2 1.5 mM                          
NaCl 420 mM                      
Glycerol 25 %                            
EDTA 0.2 mM                            
DTT 1 mM                   
AEBSF 1 Mm   
NAG-thiazoline 1 µM                             
Protease inhibitors 1 tablet pr. 10 ml 
ALLN   1/100 – 1/400 
NaF 50 mM                       
NaPPi 0.01 M                    
N3VO4 0.001 M   
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Table 8. BSA standard samples  
Well BSA  
(2 mg/ml) 
MQ-H2O Lysis 
buffer 
A+B 
solution 
A 0 µl 45 µl 5 µl 200 µl 
B 0 µl 45 µl 5 µl 200 µl 
C 3 µl 42 µl 5 µl 200 µl 
D 3 µl 42 µl 5 µl 200 µl 
E 5 µl 40 µl 5 µl 200 µl 
F 5 µl 40 µl 5 µl 200 µl 
G 8 µl 37 µl 5 µl 200 µl 
H 8 µl 37 µl 5 µl 200 µl 
 
Table 9. Running buffer (10x) for western blotting 
Ingredients   Final concentration 
Trizma base 0.25 M                             
Glycine 1.92 M 
SDS 1% 
 
Table 10A. Transfer (Blotting) buffer (10x) for western blotting                                                    
Ingredients Final concentration 
Trizma base  0.25 M                   
Glycine 1.92 M 
pH should be 8.3; do not adjust  
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Table 10B. Transfer (Blotting) buffer (1x)  
Ingredients Final concentration 
Methanol  10 % - 20 %         
10x transfer buffer  1x 
 
Table 11. Stripping buffer 
Ingredients   Final concentration 
Β-Mercaptoethanol 100 mM 
Tris-HCL, pH 6.8 62.5 mM 
SDS 2 % 
 
Table 12A. TBS (10x) 
Ingredients   Final concentration 
Trizma HCl  0.2 M 
NaCl 1,37 M       
Adjust pH to 7.6 with pure HCl 
 
Table 12B. TBST (1x) 
Ingredients   Final concentration 
10x TBS 1x 
Tween 20 0.1 % 
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